Lifestyle Modification Program to Reduce Risk of Coronary Heart Disease in Latina Women With Diabetes
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Viva Bien! trial will comprehensively evaluate a multiple risk factor intervention (diet, physical activity, stress management, social support, and smoking cessation) in a randomized effectiveness trial, which will be offered in English and Spanish to diabetic Latinas.
| Condition | Intervention |
|---|---|
|
Cardiovascular Diseases Heart Diseases Diabetes Mellitus, Type 2 |
Behavioral: Mediterranean Diet Behavioral: Physical Activity Behavioral: Stress Management Behavioral: Social Support Behavioral: Smoking Cessation Other: Control group |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | CHD Lifestyle Modification for Latinas With Diabetes |
- Adherence to the Mediterranean Diet, physical activity, stress management, and smoking cessation protocols [ Time Frame: Measured at baseline, 6, 12, and 24 months ] [ Designated as safety issue: No ]
- Hemoglobin A1c [ Time Frame: Measured at baseline, 6, 12, and 24 months ] [ Designated as safety issue: No ]
- Social support [ Time Frame: Measured at baseline, 6, 12, and 24 months ] [ Designated as safety issue: No ]
| Enrollment: | 273 |
| Study Start Date: | March 2006 |
| Study Completion Date: | August 2010 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 1
Multiple risk factor intervention, that will include diet, physical activity, stress management, social support, and smoking cessation components
|
Behavioral: Mediterranean Diet
Mediterranean dietary program
Behavioral: Physical Activity
Physical activity program
Behavioral: Stress Management
Stress management program
Behavioral: Social Support
Social support
Behavioral: Smoking Cessation
Smoking cessation program
|
|
Placebo Comparator: 2
Control group
|
Other: Control group
Usual Diabetes Care Control group
|
Detailed Description:
BACKGROUND:
Age-adjusted mortality from coronary heart disease (CHD) has been increasing in women with diabetes. On the other hand, it has been decreasing in women without diabetes and in men with and without diabetes. CHD remains the leading cause of death among women in the United States. Risks of CHD and resulting death are significantly higher among postmenopausal women; these rates are two and a half times higher among women with diabetes versus women without diabetes. Diabetes is an independent risk factor for CHD in both Latina and Anglo women, but it appears to be a greater risk factor for U.S. born Latinas, as they have higher mortality from diabetes. Among Latinas, diabetes ranks as the third leading cause of death.
DESIGN NARRATIVE:
Hispanic Americans, in particular postmenopausal Hispanic women, have an increased prevalence of type 2 diabetes, and a greater incidence of diabetes complications than non-Hispanic whites. The LLP will comprehensively evaluate a multiple risk factor intervention (diet, physical activity, stress management, social support, and smoking cessation) in a randomized effectiveness trial that will be offered in English and Spanish. The research team has shown that a similar theory-based comprehensive program, Mediterranean Lifestyle Program (MLP), is effective in improving behavioral, psychosocial, quality of life, and physiologic outcomes in postmenopausal Anglo women with type 2 diabetes. Though the results are promising, four important research issues must be addressed before such a program is ready to be put into practice. This study focuses on the following questions: 1) How should the structure and content of the MLP be modified to address the cultural characteristics of Latinas?; 2) Will the program succeed if offered within a large health plan that serves minority populations (i.e., the Kaiser Permanente site in Denver, CO)?; and 3) What are the economic implications of the LLP? The Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) evaluation framework will be used to assess how the program impacts certain dimensions that are important for carry over into clinical practice. Primary outcomes of this study will include change in behavioral measures. Secondary outcomes will include impacts on quality of life, physiologic measures, member satisfaction, and cost-effectiveness. The investigators will also study the relationship between cultural variables in this Hispanic population (e.g., family and social support; group cohesion; and acculturation) and program participation and outcomes. Substantial impacts of this study on public health include: 1) intervening with a high-risk, underserved population; 2) focusing on multiple critically important lifestyle behaviors known to reduce risk for CHD; 3) testing maintenance of behavioral changes; 4) employing methodology to estimate the program's readiness to be put into practice; and (5) measuring the robustness, reach, and cost-effectiveness of the program.
Eligibility| Ages Eligible for Study: | 30 Years to 75 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Type 2 diabetes
- Postmenopausal
- Latina
Exclusion criteria:
- Cognitive impairment or inability to comprehend program
- Has other life-threatening illnesses
- Planning to move from the area during the study
Contacts and Locations| United States, Colorado | |
| Institute for Health Research | |
| Denver, Colorado, United States, 80237 | |
| Study Chair: | Deborah J. Toobert, PhD | Oregon Research Institute |
More Information
No publications provided by Oregon Research Institute
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Oregon Research Institute |
| ClinicalTrials.gov Identifier: | NCT00233259 History of Changes |
| Other Study ID Numbers: | 327, R01HL076151, R01 HL76151 |
| Study First Received: | October 3, 2005 |
| Last Updated: | October 24, 2011 |
| Health Authority: | United States: Federal Government |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Coronary Artery Disease Myocardial Ischemia Coronary Disease Diabetes Mellitus Diabetes Mellitus, Type 2 Heart Diseases |
Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 22, 2013